AC Immune S.A.
NASDAQ: ACIU0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Andrea Pfeifer
- Employees
- 133
- Headquarters
- Lausanne, Switzerland
- IPO year
- 2016
- Market cap
- $258.5M
- Website
- https://www.acimmune.com
Loading ACIU…
Loading profile data…Frequently asked questions about ACIU
What does AC Immune S.A. (ACIU) do?
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer pla...
Where does ACIU trade?
AC Immune S.A. (ACIU) trades on the NASDAQ Global Market.
What sector is ACIU in?
AC Immune S.A. (ACIU) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of AC Immune S.A.?
Andrea Pfeifer is the chief executive officer of AC Immune S.A. (ACIU).
Where is AC Immune S.A. headquartered?
AC Immune S.A. is headquartered in Switzerland.
Does ACIU pay a dividend?
AC Immune S.A. (ACIU) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ACIU go public?
AC Immune S.A. (ACIU) completed its initial public offering in 2016.